Literature DB >> 3443145

Pharmacokinetic consequences and toxicologic implications of metyrapone-induced alterations of acetaminophen elimination in man.

R E Galinsky1, E B Nelson, D E Rollins.   

Abstract

This study examined the effect of metyrapone on the elimination rate of acetaminophen and on the apparent formation rate of acetaminophen metabolites in man. Metyrapone treatment, 1.5 g, increased the half-life of acetaminophen, decreased the fraction of the dose recovered in the urine as the glucuronide and increased the fraction of the dose recovered in urine as the sulfate and mercapturate conjugates. The apparent rate constant for the formation of acetaminophen glucuronide was significantly decreased by metyrapone while the apparent rate constants for the formation of the sulfate and mercapturic acid metabolites were unchanged or slightly increased, respectively. These data indicate that metyrapone inhibits acetaminophen glucuronidation and possibly enhances the oxidation of acetaminophen to its quantitatively minor yet highly toxic reactive metabolite. The extent to which the parallel pathways of acetaminophen elimination are also affected by inhibitors of cytochrome P-450-mediated oxidation will limit the efficacy of these types of potential antidotes for the treatment of acetaminophen overdose.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3443145     DOI: 10.1007/BF00637636

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  35 in total

1.  The quantitation of metyrapone and its reduced derivative in urine.

Authors:  D M Hannah; J G Sprunt
Journal:  J Pharm Pharmacol       Date:  1969-12       Impact factor: 3.765

2.  Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism.

Authors:  J R Mitchell; D J Jollow; W Z Potter; D C Davis; J R Gillette; B B Brodie
Journal:  J Pharmacol Exp Ther       Date:  1973-10       Impact factor: 4.030

3.  Suicide and suicide attempts by the nonmedical use of drugs.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1985-09-20       Impact factor: 17.586

4.  Synthesis of N-oxide derivatives of metyrapone and their detection as in vitro metabolites.

Authors:  P A Crooks; L A Damani; D A Cowan
Journal:  J Pharm Pharmacol       Date:  1981-05       Impact factor: 3.765

5.  Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; B Ameer; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1983-03       Impact factor: 4.030

6.  Metyrapone as a treatment for acetaminophen (paracetamol) toxicity in mice.

Authors:  M Goldstein; E B Nelson
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-01

7.  Effectiveness of methyrapone in the treatment of acetaminophen toxicity in mice.

Authors:  E B Nelson; M Montes; M Goldstein
Journal:  Toxicology       Date:  1980       Impact factor: 4.221

8.  Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans.

Authors:  J T Slattery; J M Wilson; T F Kalhorn; S D Nelson
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

9.  Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation.

Authors:  D R Abernethy; D J Greenblatt; B Ameer; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1985-08       Impact factor: 4.030

10.  Evaluation of activated charcoal-sodium sulfate combination for inhibition of acetaminophen absorption and repletion of inorganic sulfate.

Authors:  R E Galinsky; G Levy
Journal:  J Toxicol Clin Toxicol       Date:  1984-07
View more
  2 in total

Review 1.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

2.  Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.

Authors:  Mélanie Claps; Sara Cerri; Salvatore Grisanti; Barbara Lazzari; Vittorio Ferrari; Elisa Roca; Paola Perotti; Massimo Terzolo; Sandra Sigala; Alfredo Berruti
Journal:  Endocrine       Date:  2017-10-10       Impact factor: 3.633

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.